DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2

Cell Cycle

Volumn 7, Issue 11, 2008, Pages 1668-1677

  Zhang, Wen Hui ^a   Poh, Alissa ^a   Fanous, Andrew A ^a   Eastman, Alan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cdc25A; Cell cycle checkpoints; Chk1; Chk2; DNA damage; MAPKAPK2; UCN 01

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHECKPOINT KINASE RAD3; DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE APK2; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; DNA DAMAGE; GENE MUTATION; HUMAN; HUMAN CELL;

EID: 45849136737     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.11.5982     Document Type: Article

References (45)

1. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274:1664-72.
2. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9.
3. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71:543-6.
4. Weinert T. DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 1998; 94:555-8.
5. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
6. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO reports 2003; 4:671-7.
7. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcher M, Bartek J, Lukas J. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288:1425-9.
8. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO reports 2000; 1:71-9.
9. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5.
10. Zhou BBS, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev Cancer 2004; 4:115-216.
11. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GCM, Lukas J, Jackson SP. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biol 2006; 8:37-45.
12. 1/S transition and their response to DNA damage. FEBS Letts 2001; 490:117-22.
13. McGowan CH. Checking in on Cds1 (Chk2): a checkpoint kinase and tumor suppressor. BioEssays 2002; 24:502-11.
14. 2 checkpoints. Proc Natl Acad Sci USA 2002; 99:14795-800.
15. 2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003; 278:21767-73.
16. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17:402-12.
17. Carrassa L, Broggini M, Erba E, Damia G. Chk1, butnot Chk2, is involvedin the cellular responase to DNA damaging agents. Differential activity in cell expressing or not p53. Cell Cycle 2004; 3:1177-81.
18. Ho CC, Siu WY, Chow JPH, Lau A, Arooz T, Tong HY, Ng IOL, Poon RYC. The relative contribution of CHK1 and CHK2 to adriamycin-induced checkpoint. Exp Cell Res 2005; 304:1-15.
19. Bell DW, Varley JM, Szydlo TE, Kang DK, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isslebacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hChk2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-31.
20. 1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002; 99:9825-9.
21. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278:20475-9.
22. Ahn J, Urist M, Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 2003; 278:20480-9.
23. Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 1982; 79:2942-6.
24. Demarcq C, Bunch RT, Creswell D, Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Different 1994; 5:983-93.
25. 2 delay. Cancer Res 1995; 55:1643-8.
26. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase by the radiosensitizing agent, caffeine. Cancer Res 1999; 59:4375-82.
27. 2-checkpoint inhibitor. Clin Cancer Res 1996; 2:791-7.
28. 2 checkpoint function in cancer cells with disrupted p53. J Nat Cancer Inst 1996; 88:956-65.
29. 2 cell cycle checkpoints. Oncogene 2005; 24:3786-96.
30. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60:2108-12.
31. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwinica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275:5600-5.
32. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002; 62:5743-8.
33. 2/M transition and S phase progression in response to UV irradiation. Molecular Cell 2005; 17:37-48.
34. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-Deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11:175-89.
35. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of UCN-01 and the kinetics of Cdc25C activation. J Biol Chem 2002; 277:26553-64.
36. Tachibana KK, Gonzalez MA, Coleman N. Cell cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005; 205:123-9.
37. Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res 2003; 1:598-609.
38. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by Cdk2 binding and cyclin phosphorylation. Genes & Dev 1996; 10:1979-90.
39. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes & Dev 2000; 14:289-300.
40. 2 arrest. Mol Cancer Therap 2008; 7:252-62.
41. Clarke AAL, Clarke PR. DNA-dependent phosphorylation of Chk1 and claspin in a human cell-free system. Biochem J 2005; 388:705-12.
42. -/- mice. Genes & Dev 2000; 14:1439-47.
43. 2/M DNA damage checkpoint. Genes & Dev 2000; 14:1448-59.
44. 2 DNA damage checkpoint. Mol Cancer Therap 2003; 2:543-48.
45. Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 1997; 57:2366-8.